LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Sorafenib | 0.04 | uM | LJP6 | 2 | B12 | 72 | hr | 2543 | 5237 | 5438 | 0.9630 | 0.9324 |
| SK-BR-3 | Sorafenib | 0.04 | uM | LJP6 | 3 | B12 | 72 | hr | 2543 | 5153 | 5557 | 0.9272 | 0.8704 |
| SK-BR-3 | Sorafenib | 0.12 | uM | LJP6 | 1 | B11 | 72 | hr | 2543 | 5463 | 5258 | 1.0388 | 1.0740 |
| SK-BR-3 | Sorafenib | 0.12 | uM | LJP6 | 2 | B11 | 72 | hr | 2543 | 5644 | 5438 | 1.0379 | 1.0689 |
| SK-BR-3 | Sorafenib | 0.12 | uM | LJP6 | 3 | B11 | 72 | hr | 2543 | 5501 | 5557 | 0.9899 | 0.9820 |
| SK-BR-3 | Sorafenib | 0.37 | uM | LJP6 | 1 | B10 | 72 | hr | 2543 | 5516 | 5258 | 1.0489 | 1.0932 |
| SK-BR-3 | Sorafenib | 0.37 | uM | LJP6 | 2 | B10 | 72 | hr | 2543 | 5750 | 5438 | 1.0573 | 1.1044 |
| SK-BR-3 | Sorafenib | 0.37 | uM | LJP6 | 3 | B10 | 72 | hr | 2543 | 5456 | 5557 | 0.9818 | 0.9676 |
| SK-BR-3 | Sorafenib | 1.11 | uM | LJP6 | 1 | B09 | 72 | hr | 2543 | 5656 | 5258 | 1.0755 | 1.1439 |
| SK-BR-3 | Sorafenib | 1.11 | uM | LJP6 | 2 | B09 | 72 | hr | 2543 | 5713 | 5438 | 1.0505 | 1.0920 |
| SK-BR-3 | Sorafenib | 1.11 | uM | LJP6 | 3 | B09 | 72 | hr | 2543 | 5869 | 5557 | 1.0561 | 1.0992 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 1 | B08 | 72 | hr | 2543 | 5603 | 5258 | 1.0654 | 1.1247 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 2 | B08 | 72 | hr | 2543 | 5861 | 5438 | 1.0778 | 1.1414 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 3 | B08 | 72 | hr | 2543 | 5732 | 5557 | 1.0314 | 1.0556 |
| SK-BR-3 | Sorafenib | 10 | uM | LJP6 | 1 | B07 | 72 | hr | 2543 | 2932 | 5258 | 0.5575 | 0.1453 |
| SK-BR-3 | Sorafenib | 10 | uM | LJP6 | 2 | B07 | 72 | hr | 2543 | 2461 | 5438 | 0.4525 | -0.0296 |
| SK-BR-3 | Sorafenib | 10 | uM | LJP6 | 3 | B07 | 72 | hr | 2543 | 2093 | 5557 | 0.3766 | -0.1588 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 1 | I12 | 72 | hr | 2543 | 6150 | 5734 | 1.0725 | 1.1229 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 2 | I12 | 72 | hr | 2543 | 6407 | 5761 | 1.1121 | 1.1884 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 3 | I12 | 72 | hr | 2543 | 5983 | 5760 | 1.0386 | 1.0652 |
| SK-BR-3 | CP466722 | 0.12 | uM | LJP5 | 1 | I11 | 72 | hr | 2543 | 6309 | 5734 | 1.1002 | 1.1696 |
| SK-BR-3 | CP466722 | 0.12 | uM | LJP5 | 2 | I11 | 72 | hr | 2543 | 5390 | 5761 | 0.9355 | 0.8902 |
| SK-BR-3 | CP466722 | 0.12 | uM | LJP5 | 3 | I11 | 72 | hr | 2543 | 5811 | 5760 | 1.0087 | 1.0147 |
| SK-BR-3 | CP466722 | 0.37 | uM | LJP5 | 1 | I10 | 72 | hr | 2543 | 6011 | 5734 | 1.0482 | 1.0819 |
| SK-BR-3 | CP466722 | 0.37 | uM | LJP5 | 2 | I10 | 72 | hr | 2543 | 6015 | 5761 | 1.0440 | 1.0744 |